Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Clearmind Medicine Files Three Provisional Patent Applications With USPTO

The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc's Cannamide™ and classical psychedelics

byBill Haddad

February 15, 2023

1 minute read

The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s Cannamide™ and classical psychedelics

Novo Nordisk To Buy Prothena’s ATTR Amyloidosis Program For Up To $1.2B

By Vandana Singh

Today, 1:35 PM

Novo Nordisk A/S (NYSE:NVO) will acquire Prothena Corporation plc’s (NASDAQ:PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is…

NVO

Bright Minds’ Second-Gen Psychedelic Drugs Ready to Be Embraced by Investors, Big Pharma

By Ernest Dela Aglanu

Today, 1:35 PM

Bright Minds Biosciences (OTC: BMBIF), a Canadian-based biotechnology company, is developing the next-generation serotonergic drugs to treat various central nervous system (CNS) disorders.

BMBIF